U.S. FDA approves Thermo Fisher Scientific’s Oncomine Dx target test
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Subscribe To Our Newsletter & Stay Updated